| COVID-19 Vaccine |
1 |
1 |
| Heart |
0 |
0.78 |
| Vaccines |
0 |
0.65 |
| Coronary Artery Disease (CAD) |
0 |
0.63 |
| Heart Failure (HF) |
0 |
0.62 |
| Influenza |
0 |
0.58 |
| Patient Safety |
0 |
0.57 |
| Cardiovascular Risk Management |
0 |
0.54 |
| Cardiomyopathy |
0 |
0.44 |
| Immunization |
0 |
0.42 |
| Atrial Fibrillation |
0 |
0.38 |
| COVID-19 |
0 |
0.35 |
| Influenza Vaccine |
0 |
0.35 |
| Adverse Effects |
0 |
0.26 |
| Europe |
0 |
0.26 |
| Myocarditis |
0 |
0.16 |
| Thromboembolism |
0 |
0.13 |
| Hospital |
0 |
0.1 |
| Venous Thromboembolism (VTE) |
0 |
0.1 |
| Pediatric Respiratory Infections |
0 |
0.06 |
| Cancer |
0 |
0.05 |
| Cardiovascular disease |
0 |
0.05 |
| Centers for Disease Control and Prevention |
0 |
0.05 |
| Child |
0 |
0.05 |
| Geriatrics |
0 |
0.05 |
| Match |
0 |
0.05 |
| Measles |
0 |
0.05 |
| Pandemic |
0 |
0.05 |
| Pericarditis |
0 |
0.05 |
| Mechanical Ventilation |
0 |
0.03 |